Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 335

A Novel Treatment of Chronic Ulcers

Posted by fidest press agency su venerdì, 20 gennaio 2012

Laceration to the leg

Image via Wikipedia

London Bridge Bioresearch PLC (BBR) announced on the 20th of December 2011, that it has received approval for a phase 2a trial concerning Diabetic Foot Ulcer treatment with isoniazide.
The target molecule has patent protection for treatment based on Isoniazid embedded into a wound dressing and/or as a traditional tablet. Preliminary evidence has shown that isoniazide reduces the healing time of difficult to heal wounds such as pressure ulcers, chronic /venous ulcers and diabetic ulcers. Embedding Isoniazide directly into the dressing instead of applying it systematically could increase local therapeutic effect, reduce systemic side effects of the treatment and increase the ease of the use of the product. Currently no effective treatments exist for the chronic wounds.
Mary Anne Crandall in her report “World Wound Care Markets 2010” (June 2010) said many wounds do not heal at all and many lead to either amputation or death. Improving healing times and percentages of healed wounds would therefore greatly improve healthcare costs and patients’ quality of life. Moreover, Mr. Per Fischer from Fischer BioConsult ApS states: “That about 80% of the total cost of treating such wounds originates from nursing care, changing bandages, etc.; a significant reduction in healing times wound result in a very substantial reduction in health cost. In addition, the quality of life of the patients would also be greatly improved. It is therefore expected that a product with such characteristics would be in great demand.”
In 2009, the total wound care market reached $14 billion USD, with annual growth rates running at 6.5%. It is projected that the market to reach some US$19 billion in 2014. The global distribution of market value in 2009 was US/CA 41%, EU 36%, JP 6%, and ROW 17%. In 2014 it is expected to be: US/CA 38%, EU 35%, JP 8%, and ROW 19%. The present invention indicates much faster healing time, possibly up to a 50% reduction in healing time, resulting in 3 months of therapy on average for the new product, equivalent to approximately 34 dressing being used for patients at 2.5 dressing per week states Mr.Fischer.
Bridge BioResearch PLC (BBR) is a drug development company with the corporate focus on Obesity, Type II Diabetes and related metabolic disorders as well as clinical stage testing. BBR continuously monitors databases for drug development and patents within the area. Targets are carefully selected for evaluation through proprietary assessment tools.

Una Risposta a “A Novel Treatment of Chronic Ulcers”

  1. test2 said

    Magnificent web site. Plenty of useful info here. I am sending it to several buddies ans also sharing in delicious. And naturally, thanks for your sweat!


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: